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AbstrAct
Objective To identify components of a proposed blood-
borne virus (BBV) population screening programme and 
its associated consent procedure that both the public 
and health practitioners (HPs) would find acceptable. The 
proposed BBV screening system would aim to reduce late 
diagnosis of BBVs and be used in patients undergoing 
routine blood tests, aided by risk stratification software to 
target individuals at higher risk of infection.
Design A Delphi technique was used to build consensus 
among two separate groups, public participants and HPs 
in England.
Methods A survey incorporating vignettes was developed, 
with input from an external panel of experts. Over three 
rounds, 46 public participants and 37 HPs completed the 
survey, rating statements on a four-point Likert scale. 
The survey covered issues around stigma and sensitivity, 
the use of risk stratification algorithms and ‘limited’ 
patient consent (ie, preinformed of the option to ‘opt-out’). 
Consensus was defined as >70% of participants agreeing 
or disagreeing with each statement.
Results Consensus was achieved among both groups in 
terms of acceptability of the screening programme. There 
was also consensus on using patient data to risk-stratify 
screening algorithms and the need to obtain some form of 
consent around the time of drawing blood.
Conclusions This study found that the special protected 
status of HIV in England is no longer deemed necessary 
today and hinders appropriate care. We propose that a 
novel ‘limited consent procedure’ could be implemented in 
future screening programmes.
IntroductIon
Globally, around 47% of people living 
with HIV (PLWH) in 2014 were not aware 
that they were infected.1 The Joint United 
Nation Programme on HIV/AIDS (UNAID) 
‘90–90–90’ target,1 with the ambition that 
90% of PLWH will know their HIV status by 
2020, is unlikely to be achieved, especially in 
some countries with relatively low economic 
development. The situation for the other two 
main blood-borne viruses (BBVs), hepatitis 
B virus (HBV) and hepatitis C virus (HCV), 
is worse in terms of levels of undiagnosed 
infections.2–7 Failure of timely diagnoses of 
HIV or other BBVs leads to continued trans-
mission of infections as well as worse clinical 
outcomes. Late diagnosis of HIV is associated 
with a 10-fold higher risk of death in the year 
after diagnosis than early diagnosis.8 Late 
diagnosis of HBV or HCV is also associated 
with higher mortality due to liver cirrhosis, 
liver failure and liver cancer. Most HCV 
infections can now be cured, and both HBV 
and HIV infections controlled with antiviral 
therapy, if detected sufficiently early with a 
good prognosis for most patients.
In many highly economically developed 
countries, reliable tests to diagnose BBVs 
have been widely available since the 1980s 
and early 1990s. In the case of HIV, testing 
has been viewed differently to tests for 
other infections or serious medical condi-
tions; often it requires specific consent from 
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Strengths and limitations of this study
 ► A broad range of healthcare workers and members 
of the public were sampled in this nationally 
representative study.
 ► Use of a Delphi consensus building technique 
allowed an iterative approach to achieve consensus 
in an area of public health with considerable 
potential for ethical debate.
 ► The study’s methodology may be of interest to other 
countries considering such a screening programme.
 ► The application of this study’s results is limited to the 
UK, which has a different medicolegal framework in 
relation to consent, testing and screening compared 
with other countries.
 ► While we attempted to send invitations to a broad 
range of specialists and professionals for the HP 
survey, the study topic might still have attracted 
more of those with strong views.
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individuals for the test, a process termed ‘HIV excep-
tionalism’.9 This stemmed historically from when HIV 
was an untreatable disease10 and carried much social 
stigma, as HIV was widely associated with men who have 
sex with men (MSM) or intravenous drug users.11 Despite 
improvements in health outcomes, knowledge that HIV 
can infect any demographic group and attitudes towards 
MSM, such stigma still remains, both among health prac-
titioners (HPs) and the public. As a result, attempts to 
screen for HIV infections more widely, which rely on HPs 
to identify patients potentially at risk, have been hindered. 
Moreover, the necessity of obtaining specific consent for 
HIV testing has remained an additional barrier to wider 
or universal screening. Despite this barrier, HIV testing 
has become more normalised over the last decade with 
the introduction of ‘opt-out’ HIV testing,9 12 self-testing 
kits and the recommendations for universal testing in 
some clinical settings, particularly in pregnant women 
and patients attending sexually transmitted infection 
(STI) clinics.10 Testing coverage in other clinical settings 
has been less good.
Studies in the UK have shown that there has been 
missed opportunities for earlier diagnosis; high propor-
tions of patients with advanced HIV infection attended 
primary care or other healthcare facilities with indi-
cator conditions in the 1–2 years prior to diagnosis, but 
were not tested.13–16 Recognised barriers to more wide-
spread HIV testing by healthcare workers include failure 
to identify risk factors, lack of training or knowledge 
and concerns that a patient may be offended if a test is 
recommended.11 17 Efforts to increase HIV testing in clin-
ical settings, such as emergency departments, have been 
partially effective, however, required significant addi-
tional resources and are difficult to maintain.13–15 Even 
when programmes have been implemented to establish 
routine HIV or BBV testing in emergency rooms, most 
programmes have not managed to increase the propor-
tion of patients tested to above 50%.13–16
New approaches to increase HIV and BBV testing and 
to reduce rates of undiagnosed infections and late diag-
nosis are needed. Moreover, approaches to testing which 
do not require specific consent for HIV tests are likely 
to simplify screening and increase testing rates. In many 
highly economically developed countries, for example, 
the UK, around half of the population have a blood test 
of some form every year, providing a potential opportu-
nity for BBV testing via a population screening strategy.18 
Such a process might be used for universal screening, or 
to target only patients identified as being at higher risk 
of BBV infection, through risk stratification, in order 
to make testing cost-effective. Risk stratification would 
most effectively be performed by algorithms in computer 
physician order entry (CPOE) systems which might also 
interact with electronic patients records (EPR) or other 
computer health systems. Such software algorithms might 
identify those at higher risk on the basis of patient demo-
graphic characteristics, specific data or diagnostic codes 
in EPRs, previous abnormal test results (eg, lymphopenia 
or raised aminotransferase levels (ALT) or from specific 
tests being ordered on CPOEs (eg, syphilis serology). 
However, gaining specific consent for BBV screening from 
individuals at the point of drawing blood in such a system 
would be challenging. Even when using the ‘opt-out’ 
approach, many physicians would find the requirement 
to obtain specific consent from all patients who might be 
selected for screening onerous, given the time needed to 
counsel some patients. One alternative would be to gain 
limited consent, whereby patients are notified in advance 
via written communication that their blood samples may 
be tested for BBVs, and also given the opportunity to ‘opt-
out’ of the screening programme. In this case, patients 
would not be asked to consent specifically for HIV/BBV 
testing by the healthcare practitioner directly. Such a 
method of gaining limited consent might be viewed as 
both practical and reasonable, particularly given that 
the benefit of identifying people with undiagnosed BBV 
infections applies to their individual health and to society 
via reducing BBV transmission. However, it has yet to be 
determined whether this approach of limited consent 
would be considered acceptable. The aim of this study was 
to identify components of a BBV population screening 
programme and associated consent procedure that both 
the public and HPs would find acceptable.
Methods
study design
The study was designed using a Delphi method, a consen-
sus-building technique that has been used widely in 
various areas of medical practice to achieve consensus 
among HPs and patients, on acceptable and effective 
medical practice and health service provisions.19 20 An 
online survey was created using Bristol Online Survey 
(www. onlinesurveys. ac. uk) entailing four sections with 
vignettes and subsequent statements encompassing our 
research questions. Free text comment boxes at the end 
of each section allowed participants to provide additional 
comments and feedback.
Patient involvement
The only patient involvement in this study is on the 
advisory panel who aided in the process of survey devel-
opment.
Participants and recruitment
Members of the public were randomly selected through 
a commercial survey database covering potential partici-
pants across the whole of the UK and invited by email to 
fill in the questionnaire. After invitations were sent out, 
all responses were accepted sequentially until either the 
target number of respondents had completed the survey 
or the 4-week time limit for the survey had been reached. 
After this, no further participants were allowed to begin 
the survey. HPs were purposefully selected through 
relevant English National Health Service (NHS) organi-
sations. HPs were deliberately selected from a wide range 
of relevant medical specialists, general practitioners and 
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specialist nurses. Potential participants (1000 public and 
400 HPs) were emailed with a description of the study 
and a link to the online survey and asked if they would 
be willing to take part. Public participants were offered 
a financial incentive of a £5 Amazon gift voucher after 
each round to improve recruitment. In Delphi exercises, 
50 respondents are generally considered to be sufficient 
to be representative of public opinion and 30 respon-
dents sufficient to be representative of expert opinion to 
enable consensus to be achieved.20–25 A dropout rate of 
20% was expected over the three rounds, as this is found 
to be normal in other studies.25 26 Therefore, we sought to 
recruit 75 members of the public and 50 HPs to be able to 
achieve the target sample size at the end of three rounds.
survey development
The survey was developed by the research team with input 
from an external advisory panel comprising national 
experts in bioethics, medicine and Delphi methodology. 
Based on our review of the literature, we developed three 
general topic areas relevant to the proposed screening 
programme: stigma and sensitivity, the use of computer 
selection (risk stratification) algorithms/programs for 
BBV screening and patient consent. To illustrate issues 
in each area, we wrote a number of clinical vignettes, an 
approach to Delphi used previously to explore ethical 
dilemmas.23 The vignettes comprised short hypothetical 
scenarios encompassing the general topic areas that may 
be experienced by the public and HPs (see online supple-
mentary file) followed by a series of statements. Two 
statements were constructed for each question in order to 
balance negative and positive responses. Participants were 
asked to rate each statement using a 4-point Likert scale 
with a response of ‘strongly agree’, ‘agree’, ‘disagree’ and 
‘strongly disagree.’ Statements were assessed by the advi-
sory panel for readability and relevance.
data collection
Data were collected over three rounds; the process is 
summarised in figure 1. Round 1 responses were anal-
ysed, and areas requiring further investigation in round 
2 were identified. Feedback from rounds 1 and 2 was 
provided to the participants, with pie charts indicating 
group consensus and disagreement as well as the respon-
dents’ original answers. Respondents were then asked 
to reconsider the original answer in light of the group’s 
responses.
Free text comment boxes were provided at the end 
of each section for participants to provide any further 
comments, and we gathered data on participants’ age, 
gender and ethnicity. To help participants understand 
the proposed BBV screening programme, we embedded 
a link in the online survey to an informational YouTube 
video developed by DC.27
data analysis
Following completion of the third and final round, 
responses were analysed to establish areas of consensus 
and areas where consensus had not been achieved. In the 
final analysis, percentages were narrowed down to agree 
(strongly agree and agree) and disagree (strongly disagree 
and disagree); percentages of agree/disagree were calcu-
lated for each statement using SPSS V.10. Consensus 
was defined as >70% of participants agreeing/strongly 
agreeing or disagreeing/strongly disagreeing with each 
statement; this percentage is recommended to achieve 
general consensus.25 28 29 A modified continuous compar-
ative method of thematic analysis was used to analyse 
the free text comments in order to identify themes, 
allowing the determination of whether a comment made 
by one participant was a commonly shared or individual 
opinion.30
results
In round 1, a total of 119 participants (68 public and 51 
HP participants) were recruited; in round 2, 51 public and 
40 HPs completed the survey; in round 3, 46 public and 
37 HPs completed the survey. Within the final sample of 
HP respondents 55% were hospital doctors, 23% general 
practitioners and 12% specialist nurses; table 1 shows 
the demographic data collected for the public and HP 
participants. Table 2 summarises consensus achieved in 
all three rounds, and table 3 summarises common themes 
collected from all the participants free text comments.
Figure 1. The three Delphi rounds. 
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stigma and sensitivity
There was clear consensus for this section. The public and 
HPs agreed that HIV should no longer have a special status 
and should be handled like any other routine blood tests. 
In response to Question 3, HPs unanimously disagreed 
that feelings of discomfort or offending patients was an 
acceptable reason not to offer HIV tests.
the use of computer selection programs for screening
The public and HPs both agreed that a BBV screening 
programme would detect infections more often and 
would be beneficial to individual patients and society 
more widely. However, HPs contradicted themselves by 
also agreeing that the BBV screening programme was not 
acceptable as it ‘tested patients without their consent’. 
Despite this, HPs felt that computer programmes should 
be able to use patients’ information for risk stratifica-
tion. Similarly, the public agreed that the screening 
programme would help to remove the burden of identi-
fying and counselling patients. Free text comments from 
round 1 generally supported the concept of using patient 
data for risk stratification, so long as there were safeguards 
to ensure data were secure. In round 2, a follow-up ques-
tion (statements 14 and 15) confirmed that use of patient 
data for these purposes would be acceptable assuming 
data were secure.
Patient consent
Consensus was achieved in both groups on the point that 
it was not enough to inform patients that they may be 
tested for BBVs via a poster or leaflets alone. Both the 
public and the HPs agreed that getting fully informed 
consent for BBV testing was ideal. However, the public 
also agreed that any loss in patient choice (ie, autonomy) 
would be outweighed by having infections diagnosed 
earlier. For the option to offer a mix of consent options, 
rather than limited consent alone, the answers were irrec-
oncilable, with the majority of both groups agreeing with 
the two opposing statements. However, this likely instead 
reflects views that reducing healthcare costs should not 
be prioritised over obtaining sufficient consent. Free text 
comments in this section mostly supported the proposed 
consent process, but emphasised the need for all patients 
to be informed that their blood samples might be tested. 
Two new statements (16 and 17) were added in round 
2 to try and establish consensus regarding the proposed 
method of consent. There was consensus among HPs that 
patients should still be informed that their blood might 
be tested for BBVs at the point of drawing blood.
dIscussIon
This study was developed to examine attitudes of the 
public and HPs towards two mechanisms of improving 
detection of HIV and BBV infections, the use of risk 
stratification algorithms to detect patients at higher risk 
of infection and limited consent. We used an iterative 
Delphi technique with the addition of new statements in 
subsequent rounds to clarify issues raised after responses 
to prior statements. We found there was general agree-
ment among both participant groups around ending any 
persisting exceptionalism in relation to HIV testing. There 
was also consensus that a BBV screening programme 
would be beneficial and it was reasonable to use patients’ 
medical data to target those at higher risk of infection, 
assuming data were protected.
In respect to our investigation of a modified consent 
process, there was some ambiguity within both groups. 
Therefore, consensus on this point was not easily discern-
ible, indicating this form of consent posed some ethical 
dilemma. However, through iteration of rounds and 
use of free text boxes, a new and acceptable form of a 
consent process emerged from this Delphi study. We call 
this process ‘limited consent’ which involves providing 
advanced notification to all patients that their blood 
may be tested, with a reminder from a HP when blood is 
drawn, along with the option of opting out. This Delphi 
study achieved a national English sample from a range of 
HPs involved in BBV testing and the general public. Its 
finding of acceptability of a novel consent procedure and 
implications for the development of a new BBV screening 
programme, however, may be applicable only to the 
English social context.
Given the apparent sensitivity that still exists around 
offering HIV testing, it is interesting that both public 
participants and a varied range of medical and nursing HPs 
were comfortable with the concept of reducing the excep-
tionalism that has traditionally been associated with HIV 
testing and with the concept of prior consent. In devising 
the statements in the survey, we deliberately wanted to 
test how far each group might consider balancing the 
primacy of patients’ autonomy, in terms of deciding 
whether to be tested for BBVs, over the competing ethical 
principal of utilitarianism. The utilitarian argument in 
Table 1 Participants’ demographic data
Sociodemographic questions
Public
(n=46)
HP
(n=37)
Age (years)
  Age range (years) 20–73 29–61
  Mean age (years) 33 44
Gender
  Male 21 (46%) 22 (59%)
  Female 25 (54%) 15 (41%)
Ethnicity (self-defined)
  White British 33 (72%) 31 (84%)
  Asian 7 (15%) 3 (8.5%)
  Indian 3 (7%) 1 (2.5%)
  Chinese 1 (2%) 1 (2.5%)
  American 2 (4%) 0
  African 0 1 (2.5%)
HP, health practitioner.
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favour of universal or targeted screening for BBVs is that 
society as a whole benefits if more people are diagnosed 
with BBV infections since transmission is reduced, fewer 
individuals are infected and healthcare costs are reduced.
Unlike some other screening programmes, the benefits 
of the proposed BBV screening programme would extend 
more widely than to just those individuals found to be 
infected with BBVs. Another significant difference is that 
given the frequency with which patients in general have 
blood tests and potential uncertainty of which patients 
would be tested using risk stratification algorithms, 
obtaining specific and direct consent for testing each 
time a patient has blood drawn is impractical. Hence, 
obtaining prior consent from the target adult population 
with the clear option of opting out of testing may prove 
both practical and acceptable based on our study.
There is a precedent for this form of consent in the UK 
Clinical Practice Research Database,31 where all adults 
in the areas contributing medical data to this system are 
informed by letter that their fully anonymised data may 
be used for research studies or service planning unless 
they decide to ‘opt-out’ of the system. One recent study 
screening for BBVs in emergency departments has also 
successfully employed a pragmatic and limited consent 
process.16 The use of risk stratification software to iden-
tify patients at higher risk of BBV infections has recently 
been employed in the UK-based HepCATT trial, as part of 
targeted case finding for hepatitis C infection in primary 
care.32 We believe that combining such risk stratification 
software to target screening with a practical and accept-
able consent process has considerable potential to reduce 
the number of individuals with undiagnosed BBVs in 
countries with suitable health infrastructure. Further 
research into its design and implementation would be 
needed.
A recent UK study found that adding HBV/HCV tests 
to routine HIV tests in emergency departments resulted 
in significant numbers of new diagnoses of viral hepatitis 
as well as HIV, with the cost per new diagnosis well below 
the threshold for cost-effectiveness.13 This adds weight to 
the concept of screening specific or general populations 
for all three BBVs, rather than just HIV. Changing to the 
new consent process led to testing rates increasing from 
below 5% of all patients to consistently over 60% with 
mean numbers of positive results increasing from less 
than one per week to four per week.16
The process of obtaining consent in the present 
study may be viewed as a paradigm for future screening 
programmes or studies exploring alternative approaches 
to increase BBV testing. Our study adds to the evidence 
suggesting that both the public and HPs may be willing 
to accept prior consent, where HPs do not need to 
obtain specific consent for HIV or BBV testing, given 
the benefits of earlier diagnosis of BBV infections both 
to individuals and society in general. Nonetheless, there 
are potential challenges in implementing such a system 
of prior consent for BBV testing in terms of public policy 
or law. In the UK, consent for medical tests and treatment 
Table 3 Common themes from participants’ free text comments.
Stigma and sensitivity
Public
‘It should be carried out like any normal blood test…then the doctor couldn’t be offending anyone 
or be embarrassed’
‘The stigma surrounding HIV would be reduced if HIV blood tests become more routine’
HP ‘I feel there is a need for the position of testing to be brought in line with all other tests’
‘HIV testing would become more routine if it were offered more often’
The use of computer selection programs for screening
Public ‘I don’t feel comfortable with patients being selected based on age and post code…it’s acceptable for 
tests to be run based on prior results’
‘I believe that implementing it would be a tremendous service if applied ethically and sensitively’
‘If data is secured and patients aware then it should be allowed’
HP ‘We need universal not targeted screening’
‘If we are saying that anyone can get these infections, then surely we should check everyone’
‘Testing on the basis of age etc. will miss a large proportion of the population’
Patient consent
Public ‘While the BBV programme is in the public interest, it is vital that efforts are made to inform patients of 
what is happening’
‘As long as the patients are fully informed there is no problem’
‘A mixture of consent and acting in the best interests of the patient would be one of the best methods to 
ensure wide acceptability of the programme’
HP ‘People are careened for many illnesses without fully informed consent, BBV should be no different’
‘Akin to random testing for diabetes, you may inform the patient that the test is happening but would not 
necessarily discuss all the subsequent effects and treatments’
‘I am sure that as patients become more aware of this happening to their bloods, they will be more 
accepting of it and ultimately see it as ‘routine’’
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or use of medical data for specific purposes is required by 
common law,33 although in practice the precise nature of 
most blood tests ordered by clinicians are not discussed in 
detail with patients. As such, it may be feasible to test such 
a screening programme without serious legal barriers. 
In other countries where laws on consent and privacy 
relating to medical tests and use of data are different, 
adoption of such a programme may prove more problem-
atic.
conclusIon
This study has a number of strengths and limitations. 
The study used a Delphi consensus technique allowing 
an iterative approach to achieve consensus in an area 
of public health with considerable potential for ethical 
debate. We successfully recruited a broad range of health-
care workers and members of the public with a sample 
size appropriate to the methodology, thus producing a 
nationally representative sample. However, the applica-
tion of the study’s findings are restricted to the UK, given 
that other countries have different medicolegal systems 
in relation to consent and use of data, although our meth-
odology may be of interest to other countries considering 
a screening programme. Another limitation is that the 
selection process for HP participants might have led to 
self-selection bias. While we attempted to send invitations 
to a broad range of specialists and professionals for the 
HP survey, the topic might still have attracted more of 
those with strong views. However, this is a selection bias 
that applies to any kind of questionnaire study and is not 
specific only to our study.
HIV-related issues, such as treatment and social stigma, 
have developed over the past couple of decades, and asso-
ciated BBV screening programmes should reflect these 
advances. This study found that the special status of HIV 
testing in the UK may no longer be necessary today and 
is hindering appropriate screening and proposes a novel 
consent procedure that could be implemented in future 
screening programmes in the UK. Our findings could 
be used to inform the development of public policy that 
would facilitate such a BBV screening programme, as well 
as the development of professional education in terms 
of reducing the social stigma associated with HIV and 
strengthening communication between clinicians and 
their patients.
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